VBL Therapeutics GAAP EPS of -$0.12

• VBL Therapeutics press release (NASDAQ:VBLT): Q2 GAAP EPS of -$0.12.
• At June 30, 2022, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $34.5 million. VBL expects that its cash, cash equivalents, short-term bank deposits, and restricted bank deposits will be sufficient to fund currently planned operating expenses and capital expenditures for at least the next 12 months.